Lineage Cell Therapeutics Inc (AMEX: LCTX) open the trading on Wednesday, with great promise as it jumped 12.17% to $1.29, before settling in for the price of $1.15 at the close. Taking a more long-term approach, LCTX posted a 52-week range of $0.84-$1.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 119.78%. Meanwhile, its Annual Earning per share during the time was 19.25%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.56%. This publicly-traded company’s shares outstanding now amounts to $188.53 million, simultaneously with a float of $187.49 million. The organization now has a market capitalization sitting at $243.20 million. At the time of writing, stock’s 50-day Moving Average stood at $1.2126, while the 200-day Moving Average is $1.2078.
Lineage Cell Therapeutics Inc (LCTX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Lineage Cell Therapeutics Inc’s current insider ownership accounts for 0.55%, in contrast to 48.05% institutional ownership. According to the most recent insider trade that took place on Feb 08 ’24, this organization’s Director bought 96,155 shares at the rate of 1.04, making the entire transaction reach 100,001 in total value, affecting insider ownership by 158,801. Preceding that transaction, on Feb 06 ’24, Company’s Director bought 6,730,770 for 1.04, making the whole transaction’s value amount to 7,000,001. This particular insider is now the holder of 41,666,255 in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Revenue Records
Lineage Cell Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 5.56% and is forecasted to reach -0.12 in the upcoming year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Let’s observe the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). It’s Quick Ratio in the last reported quarter now stands at 2.14. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 27.17.
In the same vein, LCTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.12, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.12 at the market close of one year from today.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
[Lineage Cell Therapeutics Inc, LCTX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 18.76% While, its Average True Range was 0.1259.
Raw Stochastic average of Lineage Cell Therapeutics Inc (LCTX) in the period of the previous 100 days is set at 58.37%, which indicates a major rise in contrast to 30.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 90.64% that was higher than 83.03% volatility it exhibited in the past 100-days period.
